Aurora Cannabis exhibits a beta of 0.31, indicating its share price has been approximately 69% less volatile than the broader market over the past year. This comparatively low volatility suggests that the company’s stock may offer a more stable ride for investors seeking reduced exposure to market swings, although it also reflects the firm’s sensitivity to sector-specific regulatory and demand dynamics in both medical and recreational cannabis markets.

In its most recent fiscal year, Aurora Cannabis reported gross revenues of $246.72 million and net income of $1.63 million, underscoring modest profitability following several consecutive years of losses. The company’s earnings per share stood at negative $0.69, while its price-to-sales ratio of 0.97 and negative price-to-earnings multiple of approximately –6.13 highlight a valuation that may appeal to value-oriented investors, given the near-break-even sales multiple and the expectation of margin improvements as operational efficiencies take hold.

Institutional investors hold 47.6% of Aurora Cannabis’s outstanding shares, signaling substantial confidence from hedge funds, pension funds and other large asset managers in the company’s long-term growth trajectory. By contrast, no shares are currently held by insiders, which may reflect management’s decision to focus on reinvestment and debt reduction rather than share purchases at current price levels.

Among recent sell-side recommendations, Aurora Cannabis has received one sell rating, one hold rating and one strong-buy rating, resulting in an average rating score of 2.33 on a 1-to-5 scale (with lower scores indicating more bullish consensus). Profitability ratios remain under pressure, with a net margin of –15.96%, return on equity of –0.58% and return on assets of –0.42%, though management forecasts that ongoing cost optimization and favorable product mix shifts in core Canadian and European operations will drive a return to positive margins within the next two fiscal years.